You just read:

First Patient Dosed In Pivotal Biomarker-Guided Phase 3 Study Of First Line Therapy With DB102 (enzastaurin) + R-CHOP In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

News provided by

Denovo Biopharma LLC

Apr 03, 2018, 16:19 ET